These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10923926)

  • 1. Cytopathic effect of in situ gene therapy in prostate cancer.
    Ayala G; Wheeler TM; Shalev M; Thompson TC; Miles B; Aguilar-Cordova E; Chakraborty S; Kadmon D
    Hum Pathol; 2000 Jul; 31(7):866-70. PubMed ID: 10923926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer.
    Ayala G; Satoh T; Li R; Shalev M; Gdor Y; Aguilar-Cordova E; Frolov A; Wheeler TM; Miles BJ; Rauen K; Teh BS; Butler EB; Thompson TC; Kadmon D
    Mol Ther; 2006 Apr; 13(4):716-28. PubMed ID: 16480930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.
    Satoh T; Teh BS; Timme TL; Mai WY; Gdor Y; Kusaka N; Fujita T; Pramudji CK; Vlachaki MT; Ayala G; Wheeler T; Amato R; Miles BJ; Kadmon D; Butler EB; Thompson TC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):562-71. PubMed ID: 15145177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
    van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
    Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.
    Shalev M; Kadmon D; Teh BS; Butler EB; Aguilar-Cordova E; Thompson TC; Herman JR; Adler HL; Scardino PT; Miles BJ
    J Urol; 2000 Jun; 163(6):1747-50. PubMed ID: 10799174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bystander effect mediated by herpes simplex virus-thymidine kinase/ganciclovir approach on prostatic cancer cells and its regulation].
    Xing Y; Lu G; Xiao Y; Zeng F; Zhang Q; Xiong P; Feng W
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1484-7. PubMed ID: 12509912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
    Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
    Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer.
    Mäkinen K; Loimas S; Wahlfors J; Alhava E; Jänne J
    J Gene Med; 2000; 2(5):361-7. PubMed ID: 11045430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer.
    Kagaya T; Nakamoto Y; Sakai Y; Tsuchiyama T; Yagita H; Mukaida N; Kaneko S
    Cancer Gene Ther; 2006 Apr; 13(4):357-66. PubMed ID: 16224495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy.
    Loimas S; Toppinen MR; Visakorpi T; Jänne J; Wahlfors J
    Cancer Gene Ther; 2001 Feb; 8(2):137-44. PubMed ID: 11263529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma.
    Sakai Y; Kaneko S; Nakamoto Y; Kagaya T; Mukaida N; Kobayashi K
    Cancer Gene Ther; 2001 Oct; 8(10):695-704. PubMed ID: 11687892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques.
    Eaton JD; Perry MJ; Todryk SM; Mazucco RA; Kirby RS; Griffiths JR; Dalgleish AG
    Gene Ther; 2001 Apr; 8(7):557-67. PubMed ID: 11319623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
    Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
    Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [All-trans retinoic acid enhances bystander effect of suicide-gene therapy against androgen-unresponsive prostate cancer].
    Chen WG; Yan CY; Hou JQ; Wen DG; Pu JX; Wang HB
    Zhonghua Nan Ke Xue; 2008 Feb; 14(2):122-5. PubMed ID: 18390175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.
    Fujita T; Teh BS; Timme TL; Mai WY; Satoh T; Kusaka N; Naruishi K; Fattah EA; Aguilar-Cordova E; Butler EB; Thompson TC
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):84-90. PubMed ID: 16472937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.
    Moriuchi S; Krisky DM; Marconi PC; Tamura M; Shimizu K; Yoshimine T; Cohen JB; Glorioso JC
    Gene Ther; 2000 Sep; 7(17):1483-90. PubMed ID: 11001368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.